Rexahn Pharmaceuticals, Inc. Provides Third Quarter 2009 Business Update
11/17/2009 9:32:05 AM
More...
|
Rexahn Pharmaceuticals, Inc.'s Archexin(TM) Recognized as One of Windhover Information Inc.'s Top 10 Most Promising Oncology Products
11/9/2009 10:18:50 AM
More...
|
Rexahn Pharmaceuticals, Inc. Announces Closing of Public Equity Offering
10/26/2009 9:56:12 AM
More...
|
New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn Pharmaceuticals, Inc.' Archexin(TM) as Potent Inhibitor of Human Cancer Cell Growth
10/22/2009 9:28:55 AM
More...
|
Rexahn Pharmaceuticals, Inc. To Raise $5 Million in Registered Direct Offering
10/19/2009 12:15:02 PM
More...
|
Rexahn Pharmaceuticals, Inc. Reports Positive Top-line Phase IIa Data for Serdaxin(TM) in Patients with Major Depressive Disorder (MDD)
10/19/2009 9:05:50 AM
More...
|
Rexahn Pharmaceuticals, Inc. to Present at the 8th Annual Bio Investor Forum on October 29, 2009
10/15/2009 8:25:37 AM
More...
|
Rexahn Pharmaceuticals, Inc. Provides Second Quarter 2009 Business Update
8/17/2009 8:31:47 AM
More...
|
Rexahn Pharmaceuticals, Inc. and Korea Research Institute of Chemical Technology Form Licensing Partnership
7/13/2009 8:54:52 AM
More...
|
Rexahn Pharmaceuticals, Inc. Regains Compliance with NYSE Amex Listing Requirements
7/8/2009 8:22:50 AM
More...
|
|